Avian Influenza in Wales: Surveillance and Control

Etiology and Virological Basis

Avian influenza virus (AIV) is an enveloped, negative-sense, single-stranded RNA virus belonging to the family Orthomyxoviridae, genus Influenzavirus A [1]. The viral genome comprises eight segmented RNA segments encoding at least 11 proteins, including the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) [1]. These glycoproteins determine the virus subtype and are the primary targets of the host humoral immune response [1]. The HA glycoprotein mediates viral attachment to sialic acid receptors on host epithelial cells, while NA facilitates viral release by cleaving sialic acid residues [1]. The segmented nature of the genome permits genetic reassortment when two or more AIV strains coinfect a single cell, a mechanism that can generate novel subtypes with pandemic potential [1].

AIV subtypes are classified as low pathogenicity (LPAI) or high pathogenicity (HPAI) based on their virulence in gallinaceous poultry, particularly chickens [2]. LPAI viruses typically cause mild or subclinical respiratory and enteric infections, whereas HPAI viruses produce systemic, often fatal disease [2]. The molecular determinant of high pathogenicity resides in the HA0 cleavage site; HPAI viruses possess multiple basic amino acids at this site, allowing cleavage by ubiquitous host proteases and enabling systemic replication [2]. In contrast, LPAI viruses have a monobasic cleavage site restricted to trypsin-like proteases present in the respiratory and intestinal tracts [2]. All HPAI viruses identified to date belong to the H5 or H7 subtypes, although not all H5 or H7 viruses are highly pathogenic [2].

Epidemiology of Avian Influenza in Wales

Wales, as a constituent country of the United Kingdom, maintains a significant poultry sector comprising commercial broiler, layer, breeder, and turkey operations, as well as a substantial population of backyard and free-range flocks [3]. The epidemiology of avian influenza in Wales is shaped by the interplay between domestic poultry populations and wild bird reservoirs, particularly waterfowl and shorebirds, which serve as the natural reservoir for LPAI viruses [3]. Wild Anseriformes (ducks, geese, swans) and Charadriiformes (gulls, waders) are asymptomatic carriers of a broad diversity of AIV subtypes and can introduce virus into poultry holdings via direct contact or environmental contamination [3].

Outbreaks of HPAI in Wales have historically been linked to incursions from wild bird populations, often coinciding with seasonal migration patterns [3]. The introduction of HPAI H5N1, H5N8, and H5N6 clades into European poultry flocks during the 2010s and 2020s demonstrated the vulnerability of Welsh poultry to these epizootics [3]. The Welsh Government, in coordination with the Animal and Plant Health Agency (APHA), implements enhanced surveillance during periods of heightened risk, such as autumn and winter migration [3]. Epidemiological investigations of Welsh outbreaks have consistently identified wild bird contact, contaminated fomites, and breaches in biosecurity as primary risk factors [3].

Clinical Signs and Pathological Findings

Clinical manifestations of AIV infection in poultry depend on virus pathogenicity, host species, age, immune status, and concurrent infections [4]. LPAI infections in gallinaceous birds often present with mild respiratory signs including sneezing, coughing, ocular discharge, and sinusitis, accompanied by decreased feed and water intake, reduced egg production, and eggshell abnormalities [4]. In turkeys, LPAI may cause more pronounced respiratory distress and sinusitis compared to chickens [4].

HPAI infection produces a rapidly progressive, peracute to acute disease with high morbidity and mortality [4]. Clinical signs include severe depression, cyanosis of the comb and wattles, edema of the head and neck, petechial hemorrhages on the shanks, and neurological signs such as ataxia, torticollis, and paralysis [4]. Mortality rates in susceptible chicken flocks can approach 100% within 48 to 72 hours of initial clinical signs [4]. In waterfowl, HPAI infection may be subclinical or produce mild neurological signs, although some H5N1 clades have caused significant mortality in wild swans and geese [4].

Pathological findings in HPAI cases include severe congestion and edema of the subcutaneous tissues of the head and neck, multifocal hemorrhages on visceral organs, and necrotic foci in the pancreas, spleen, and liver [4]. Histologically, HPAI causes widespread necrosis of endothelial cells and parenchymal cells, with evidence of viral antigen in multiple tissues by immunohistochemistry [4]. LPAI pathology is typically confined to the respiratory tract and oviduct, with catarrhal tracheitis, airsacculitis, and regression of ovarian follicles [4].

Surveillance Systems in Wales

Surveillance for avian influenza in Wales operates under a multi-tiered framework aligned with European Union and World Organisation for Animal Health (WOAH) standards [5]. Passive surveillance relies on the mandatory reporting of notifiable disease suspicion by poultry keepers and veterinarians to the APHA [5]. Active surveillance includes targeted sampling of commercial flocks, backyard flocks, and wild birds [5]. Serological surveillance using hemagglutination inhibition (HI) and enzyme-linked immunosorbent assays (ELISA) detects antibodies against AIV nucleoprotein or specific HA subtypes [5]. Virological surveillance employs real-time reverse transcription polymerase chain reaction (rRT-PCR) on oropharyngeal and cloacal swabs, with positive samples undergoing virus isolation in embryonated chicken eggs and subsequent subtyping by sequencing [5].

Wild bird surveillance in Wales is coordinated through the APHA and the British Trust for Ornithology, focusing on sentinel species such as mute swans, mallards, and greylag geese [5]. Sampling of wild bird feces, carcasses, and trapped birds provides early warning of AIV incursions [5]. The Welsh Government also conducts risk-based surveillance during high-risk periods, targeting holdings in high-density poultry areas and those with poor biosecurity records [5].

flowchart TD
    A[Clinical suspicion or routine surveillance], > B[Sample collection: oropharyngeal and cloacal swabs, blood]
    B, > C{Diagnostic testing}
    C, > D[rRT-PCR for AIV matrix gene]
    D, > E{Result}
    E, >|Positive| F[Subtyping by HA/NA specific rRT-PCR]
    E, >|Negative| G[No further action]
    F, > H[Virus isolation in embryonated eggs]
    H, > I[Full genome sequencing]
    I, > J[Pathotyping: HA0 cleavage site analysis]
    J, > K{Pathotype}
    K, >|HPAI| L[APHA notification, culling, movement restrictions]
    K, >|LPAI| M[Risk assessment, enhanced surveillance]
    L, > N[Epidemiological investigation]
    M, > N
    N, > O[Report to WOAH and Welsh Government]

Diagnostic Approaches

Molecular diagnostics form the cornerstone of AIV detection in Wales [6]. The recommended rRT-PCR assay targets the matrix (M) gene, which is highly conserved across all influenza A subtypes, providing sensitive and specific detection [6]. Positive samples are further tested using subtype-specific rRT-PCR assays for H5, H7, and other relevant HA subtypes, as well as N1, N3, N8, and other NA subtypes [6]. The limit of detection for these assays is typically in the range of 10 to 100 viral RNA copies per reaction [6].

Virus isolation in embryonated specific-pathogen-free (SPF) chicken eggs remains the gold standard for obtaining high-titer virus for antigenic and genetic characterization [6]. Allantoic fluid harvested from inoculated eggs is tested for hemagglutinating activity using chicken or turkey erythrocytes [6]. Hemagglutination inhibition (HI) assays using reference antisera provide subtype identification, although this method is increasingly supplemented by sequencing [6].

Full genome sequencing using high-throughput sequencing platforms enables detailed phylogenetic and molecular epidemiological analyses [6]. Sequence data inform the determination of pathogenicity via HA0 cleavage site motif analysis, the identification of molecular markers of mammalian adaptation (e.g., E627K in PB2), and the tracking of viral spread across geographic regions [6]. The Welsh APHA laboratory network participates in international data-sharing initiatives such as GISAID to facilitate real-time outbreak response [6].

Serological surveillance in unvaccinated flocks uses commercial competitive ELISA kits targeting antibodies against the AIV nucleoprotein, which is group-specific [6]. HI assays using standardized antigens provide subtype-specific serology, which is useful for monitoring LPAI circulation in sentinel flocks [6]. Serology is less useful for HPAI detection due to the rapid mortality that precludes seroconversion [6].

Differential Diagnosis

The clinical signs of avian influenza overlap with several other respiratory and systemic diseases of poultry [7]. Differential diagnoses for LPAI include infectious bronchitis virus (IBV), Newcastle disease virus (NDV), avian metapneumovirus (aMPV), Mycoplasma gallisepticum, and Ornithobacterium rhinotracheale [7]. For HPAI, the primary differential is velogenic NDV, which produces similar neurological and hemorrhagic signs [7]. Other differentials include fowl cholera (Pasteurella multocida), acute colibacillosis, and toxicoses [7]. Laboratory confirmation by rRT-PCR is essential to differentiate AIV from these pathogens [7].

Control Strategies

Control of avian influenza in Wales is based on early detection, rapid response, and biosecurity [8]. Upon confirmation of HPAI in a holding, the APHA implements immediate stamping out (culling of all poultry on the infected premises), movement restrictions within a protection zone (3 km radius) and a surveillance zone (10 km radius), and enhanced surveillance of surrounding holdings [8]. Infected premises undergo thorough cleaning and disinfection followed by a fallow period before restocking [8].

Biosecurity measures are the primary preventive strategy [8]. These include preventing contact between domestic poultry and wild birds, using dedicated footwear and clothing for personnel, disinfecting vehicles and equipment, controlling vermin, and implementing all-in/all-out flock management [8]. The Welsh Government provides statutory biosecurity guidance and conducts inspections to ensure compliance [8].

Vaccination against AIV is not routinely practiced in Wales due to trade restrictions and the risk of silent circulation of virus in vaccinated flocks [8]. However, emergency vaccination may be considered under specific circumstances, such as in valuable breeding flocks or zoological collections, subject to risk assessment and regulatory approval [8]. Vaccines, if used, must be DIVA (Differentiating Infected from Vaccinated Animals) compatible, typically using inactivated whole virus vaccines with a different NA subtype to the circulating field strain [8].

Treatment

There is no specific antiviral treatment for AIV infection in poultry [9]. Supportive care is not recommended for HPAI due to the rapid course of disease and the risk of virus dissemination [9]. In LPAI outbreaks, antimicrobial therapy may be used to control secondary bacterial infections, but this does not affect the viral infection itself [9]. The use of antiviral drugs such as oseltamivir in poultry is prohibited in the UK due to concerns about generating resistant virus strains that could compromise human pandemic preparedness [9].

Public Health and One Health Considerations

Although this article focuses on veterinary aspects, avian influenza in Wales is managed within a One Health framework that recognizes the zoonotic potential of certain AIV subtypes, particularly H5N1, H5N6, and H7N9 [10]. The Welsh Government collaborates with Public Health Wales to monitor poultry workers and responders for signs of infection and to provide personal protective equipment (PPE) guidance [10]. The risk of human infection from infected poultry is considered low with appropriate biosecurity and PPE [10].

Conclusion

Avian influenza in Wales represents a persistent threat to the poultry industry and wild bird populations. The combination of robust passive and active surveillance, rapid molecular diagnostics, strict biosecurity protocols, and coordinated outbreak response has been effective in detecting and controlling incursions. Continued investment in surveillance infrastructure, genomic epidemiology, and keeper education is essential to mitigate the impact of this notifiable disease. The integration of Welsh surveillance data into European and global networks enhances preparedness for emerging AIV strains.

References

[1] Swayne, D.E., Suarez, D.L., and Sims, L.D. (2020). Influenza. In: Swayne, D.E. (ed.), Diseases of Poultry, 14th edition. Wiley-Blackwell, Hoboken, NJ, pp. 210-256.

[2] World Organisation for Animal Health (WOAH). (2023). Avian Influenza (Infection with High Pathogenicity Avian Influenza Viruses). In: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. WOAH, Paris, France.

[3] Animal and Plant Health Agency (APHA). (2023). Avian Influenza Outbreak Assessment: Wales. APHA, Cardiff, UK.

[4] Pantin-Jackwood, M.J. and Swayne, D.E. (2009). Pathogenesis and pathobiology of avian influenza virus infection in birds. Revue Scientifique et Technique (International Office of Epizootics), 28(1), pp. 113-136.

[5] Welsh Government. (2023). Avian Influenza Prevention Zone and Surveillance Strategy for Wales. Welsh Government, Cardiff, UK.

[6] Spackman, E. and Suarez, D.L. (2008). Avian influenza virus detection and quantitation by real-time RT-PCR. Methods in Molecular Biology, 436, pp. 53-61.

[7] Jackwood, M.W. (2020). Differential diagnosis of avian respiratory diseases. In: Swayne, D.E. (ed.), Diseases of Poultry, 14th edition. Wiley-Blackwell, Hoboken, NJ, pp. 135-148.

[8] European Commission. (2023). Commission Delegated Regulation (EU) 2023/361 on the control of avian influenza. Official Journal of the European Union.

[9] Alexander, D.J. (2007). An overview of the epidemiology of avian influenza. Vaccine, 25(30), pp. 5637-5644.

[10] World Health Organization (WHO). (2023). Avian Influenza: Guidance for Surveillance and Response. WHO, Geneva, Switzerland. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.